Congrats to Big Pharma on Finding a New Way to Profit Off of HIV Prevention
Gilead, the company that makes Truvada, just got FDA approval for Descovy, another form of PrEP. It costs nearly $1,800 a month without insurance coverage.
The FDA Has Approved Generic PrEP—but Access May Remain Difficult
Experts cited complicated factors, like patient and doctor awareness and the unique way the US HIV medication market functions, as reasons not to get your hopes up.
Why Isn’t a Revolutionary HIV Medication Getting to Sex Workers?
Thanks to widespread stigma and cultural incompetency within the health-care system, Truvada is not reaching the people who may need it most.